ENDRA Life Sciences Inc. Warrants Logo

ENDRA Life Sciences Inc. Warrants

NDRAW

(1.2)
Stock Price

0,03 USD

-88.18% ROA

-126.46% ROE

-0.04x PER

Market Cap.

0,00 USD

6.3% DER

0% Yield

0% NPM

ENDRA Life Sciences Inc. Warrants Stock Analysis

ENDRA Life Sciences Inc. Warrants Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ENDRA Life Sciences Inc. Warrants Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.04x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (6%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-126.46%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-88.18%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

ENDRA Life Sciences Inc. Warrants Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ENDRA Life Sciences Inc. Warrants Technical Stock Analysis
# Analysis Recommendation

ENDRA Life Sciences Inc. Warrants Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ENDRA Life Sciences Inc. Warrants Revenue
Year Revenue Growth
2014 559.355
2015 1.410.064 60.33%
2016 515.582 -173.49%
2017 351.622 -46.63%
2018 6.174 -5595.21%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ENDRA Life Sciences Inc. Warrants Research and Development Expenses
Year Research and Development Expenses Growth
2014 873.167
2015 1.038.878 15.95%
2016 495.377 -109.71%
2017 1.931.075 74.35%
2018 4.722.465 59.11%
2019 6.574.999 28.18%
2020 5.917.944 -11.1%
2021 5.482.531 -7.94%
2022 4.852.088 -12.99%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ENDRA Life Sciences Inc. Warrants General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 896.926
2015 1.222.888 26.66%
2016 1.541.956 20.69%
2017 2.628.615 41.34%
2018 3.489.894 24.68%
2019 3.443.725 -1.34%
2020 4.420.187 22.09%
2021 4.940.398 10.53%
2022 5.209.376 5.16%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ENDRA Life Sciences Inc. Warrants EBITDA
Year EBITDA Growth
2014 -2.143.636
2015 -2.206.979 2.87%
2016 -2.710.433 18.57%
2017 -4.604.009 41.13%
2018 -8.998.704 48.84%
2019 -12.699.792 29.14%
2020 -11.393.733 -11.46%
2021 -11.006.835 -3.52%
2022 -11.223.940 1.93%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ENDRA Life Sciences Inc. Warrants Gross Profit
Year Gross Profit Growth
2014 300.210
2015 743.831 59.64%
2016 279.704 -165.94%
2017 178.840 -56.4%
2018 6.174 -2796.66%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ENDRA Life Sciences Inc. Warrants Net Profit
Year Net Profit Growth
2014 -2.180.878
2015 -2.279.204 4.31%
2016 -2.775.369 17.88%
2017 -5.376.962 48.38%
2018 -9.796.261 45.11%
2019 -17.525.741 44.1%
2020 -11.725.501 -49.47%
2021 -11.352.321 -3.29%
2022 -11.432.808 0.7%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ENDRA Life Sciences Inc. Warrants Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 -1
2015 -1 0%
2016 -1 100%
2017 -2 0%
2018 -2 50%
2019 -2 0%
2020 -1 0%
2021 -1 0%
2022 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ENDRA Life Sciences Inc. Warrants Free Cashflow
Year Free Cashflow Growth
2014 -1.672.600
2015 -976.538 -71.28%
2016 -1.315.623 25.77%
2017 -3.300.914 60.14%
2018 -7.802.481 57.69%
2019 -8.632.446 9.61%
2020 -10.821.928 20.23%
2021 -11.167.384 3.09%
2022 -3.188.223 -250.27%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ENDRA Life Sciences Inc. Warrants Operating Cashflow
Year Operating Cashflow Growth
2014 -1.397.229
2015 -842.727 -65.8%
2016 -1.315.623 35.94%
2017 -3.300.914 60.14%
2018 -7.702.481 57.14%
2019 -8.588.851 10.32%
2020 -10.746.595 20.08%
2021 -11.122.384 3.38%
2022 -3.098.870 -258.92%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ENDRA Life Sciences Inc. Warrants Capital Expenditure
Year Capital Expenditure Growth
2014 275.371
2015 133.811 -105.79%
2016 0 0%
2017 0 0%
2018 100.000 100%
2019 43.595 -129.38%
2020 75.333 42.13%
2021 45.000 -67.41%
2022 89.353 49.64%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ENDRA Life Sciences Inc. Warrants Equity
Year Equity Growth
2014 605.333
2015 250.300 -141.84%
2016 -893.767 128.01%
2017 5.275.488 116.94%
2018 6.248.208 15.57%
2019 4.760.670 -31.25%
2020 7.169.321 33.6%
2021 10.784.246 33.52%
2022 9.068.633 -18.92%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ENDRA Life Sciences Inc. Warrants Assets
Year Assets Growth
2014 702.934
2015 486.722 -44.42%
2016 490.761 0.82%
2017 6.123.702 91.99%
2018 7.222.791 15.22%
2019 7.176.269 -0.65%
2020 8.425.964 14.83%
2021 12.874.644 34.55%
2022 10.936.692 -17.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ENDRA Life Sciences Inc. Warrants Liabilities
Year Liabilities Growth
2014 97.601
2015 236.422 58.72%
2016 1.384.528 82.92%
2017 848.214 -63.23%
2018 974.583 12.97%
2019 2.415.599 59.65%
2020 1.595.655 -51.39%
2021 2.090.398 23.67%
2022 1.868.059 -11.9%

ENDRA Life Sciences Inc. Warrants Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.82
Price to Earning Ratio
-0.04x
Price To Sales Ratio
0x
POCF Ratio
-0.04
PFCF Ratio
0
Price to Book Ratio
0.04
EV to Sales
0
EV Over EBITDA
0.8
EV to Operating CashFlow
0.79
EV to FreeCashFlow
0.79
Earnings Yield
-27.41
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
3.8
Graham NetNet
0.58

Income Statement Metrics

Net Income per Share
-0.82
Income Quality
0.98
ROE
-1.26
Return On Assets
-0.88
Return On Capital Employed
-0.99
Net Income per EBT
1.01
EBT Per Ebit
1
Ebit per Revenue
0
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.01
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.81
Free CashFlow per Share
-0.81
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
-0.2
Return on Invested Capital
-0.99
Return on Tangible Assets
-0.88
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,69
Book Value per Share
0,78
Tangible Book Value per Share
0.78
Shareholders Equity per Share
0.78
Interest Debt per Share
0.05
Debt to Equity
0.06
Debt to Assets
0.05
Net Debt to EBITDA
0.8
Current Ratio
7.83
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0.06
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
937099
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ENDRA Life Sciences Inc. Warrants Dividends
Year Dividends Growth

ENDRA Life Sciences Inc. Warrants Profile

About ENDRA Life Sciences Inc. Warrants

CEO
None
Employee
0
Address

,

ENDRA Life Sciences Inc. Warrants Executives & BODs

ENDRA Life Sciences Inc. Warrants Executives & BODs
# Name Age

ENDRA Life Sciences Inc. Warrants Competitors